"Aminopyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pyridines substituted in any position with an amino group. May be hydrogenated, but must retain at least one double bond.
| Descriptor ID |
D000631
|
| MeSH Number(s) |
D02.092.080 D03.383.725.050
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aminopyridines".
Below are MeSH descriptors whose meaning is more specific than "Aminopyridines".
This graph shows the total number of publications written about "Aminopyridines" by people in this website by year, and whether "Aminopyridines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2015 | 1 | 3 | 4 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 3 | 3 |
| 2018 | 2 | 1 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 3 | 0 | 3 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 3 | 4 |
| 2024 | 2 | 2 | 4 |
| 2025 | 1 | 1 | 2 |
| 2026 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aminopyridines" by people in Profiles.
-
Surgical window of opportunity clinical trial of abemaciclib and letrozole for endometrioid adenocarcinoma of the endometrium. Gynecol Oncol. 2026 Aug; 211:171-177.
-
Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data. Clin Cancer Res. 2026 Jan 16; 32(2):428-437.
-
EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma. Cell Death Dis. 2025 Jul 14; 16(1):522.
-
CDK4/6 inhibition in early and advanced hormone receptor-positive, HER2-negative breast cancer. Expert Rev Anticancer Ther. 2025 Jun; 25(6):675-686.
-
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer. J Oncol Pharm Pract. 2026 Jun; 32(4):641-647.
-
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast Cancer Res Treat. 2025 Feb; 209(3):487-492.
-
Identification of CDK4/6 Inhibitors as Small Molecule NLRP3 Inflammasome Activators that Facilitate IL-1ß Secretion and T Cell Adjuvanticity. J Med Chem. 2024 09 12; 67(17):14974-14985.
-
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. Blood Adv. 2024 01 23; 8(2):429-440.
-
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 04; 204(4):1238-1242.
-
NAD+ Metabolism Generates a Metabolic Vulnerability in Endocrine-Resistant Metastatic Breast Tumors in Females. Endocrinology. 2023 04 17; 164(6).